Myopia And Presbyopia Treatment Market – Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Myopia Treatment Type (Corrective, Surgical, Drugs), By Presbyopia Treatment Type (Prescription, Contact Lenses, Intraocular Lenses, Refractive Surgery), By Region and Competition, 2021-2031F

Forecast Period	2027-2031
Market Size (2025)	USD 21.95 Billion
CAGR (2026-2031)	8.28%
Fastest Growing Segment	Prescription
Largest Market	North America
Market Size (2031)	USD 35.38 Billion

Market Overview

The Global Myopia And Presbyopia Treatment Market will grow from USD 21.95 Billion in 2025 to USD 35.38 Billion by 2031 at a 8.28% CAGR. The Global Myopia and Presbyopia Treatment Market consists of corrective medical solutions including prescription eyeglasses, contact lenses, refractive surgeries, and pharmacological agents intended to rectify nearsightedness and vision loss associated with aging. This sector is primarily driven by demographic shifts such as the aging global population and the rising prevalence of myopia attributed to lifestyle changes like reduced outdoor activity and increased digital consumption. Furthermore, latent consumer demand for spectacle independence acts as a powerful catalyst for the adoption of modern corrective technologies. According to the Contact Lens Institute, in 2024, data revealed that 47.8 percent of glasses wearers who had never tried contact lenses expressed a high interest in doing so, indicating a substantial opportunity for market penetration.

Nevertheless, a significant challenge impeding broader market expansion is the prohibitive cost and limited accessibility of advanced corrective procedures in emerging economies. The high financial investment required for premium refractive surgeries and specialized management devices often restricts their adoption to wealthier demographics, thereby slowing growth in developing regions where healthcare infrastructure remains less established.

Key Market Drivers

The escalating global prevalence of myopia and presbyopia is fundamentally reshaping the treatment landscape, serving as a primary catalyst for market growth. This surge is increasingly linked to lifestyle factors such as rapid urbanization and intense digital consumption, which have accelerated the onset of refractive errors in younger demographics. Consequently, there is a heightened urgency for effective management strategies beyond traditional corrective eyewear, driving the adoption of specialized control lenses and interventions. According to the Association of Optometrists, October 2024, in the 'Examining the global prevalence of myopia' article, researchers estimated the current global prevalence of myopia among children and young people to be 30.47%. This expanding patient pool is compelling manufacturers to innovate rapidly, ensuring a steady stream of advanced treatment options to address this critical public health challenge.

Simultaneously, the emergence of novel pharmacological therapies and corrective eye drops is revolutionizing patient care by offering non-invasive alternatives to surgery and spectacles. Recent commercial launches of presbyopia-correcting drops and low-dose atropine for myopia indicate a significant shift toward pharmaceutical management of vision impairment. This trend is supported by substantial capital inflows aimed at commercializing these breakthrough solutions. According to Optometry Times, October 2024, in the 'Orasis Pharmaceuticals secures financing for commercial launch of presbyopia-correcting drops' article, Orasis Pharmaceuticals secured $78 million in financing to support the commercial launch of Qlosi. This robust investment climate underscores the sector's financial vitality, further evidenced by broader industry performance. According to The Vision Council, in 2025, the U.S. optical industry achieved a total market value of $68.3 billion in 2024.

Download Free Sample Report

Key Market Challenges

The prohibitive cost and limited accessibility of advanced corrective procedures constitute a primary obstruction to the expansion of the global market. High financial barriers associated with premium refractive surgeries and specialized pharmacological agents effectively restrict the adoption of these solutions to affluent demographics. This economic stratification prevents the mass market, particularly in developing nations, from transitioning away from traditional, lower-cost correctives like standard eyeglasses. Consequently, the addressable market size is artificially capped, as a vast majority of the patient population cannot afford the significant out-of-pocket leverage required for modern interventions, despite the clinical benefits they offer.

This challenge is exacerbated by the substantial price tag attached to elective procedures, which often lack comprehensive insurance coverage. According to the Refractive Surgery Council, in 2024, the average cost of LASIK eye surgery was approximately $4,400 for a bilateral procedure. Such a high price point is prohibitive in emerging economies where disposable income is limited and healthcare infrastructure is often insufficient to support widespread access to such specialized treatments. As a result, market penetration in these high-growth potential regions remains sluggish, hampering the overall revenue trajectory of the industry.

Key Market Trends

The proliferation of next-generation myopia control spectacle lenses is establishing a new standard of care for pediatric patients, moving beyond traditional single-vision correction. These advanced lenses utilize specialized optical defocus technologies to actively slow eyeball elongation, contrasting with standard glasses that merely correct refractive error. This shift is driven by clinical evidence of their efficacy, prompting adoption as a primary non-invasive intervention. The commercial success of these products highlights their growing importance in the treatment mix. According to EssilorLuxottica, February 2025, in the 'Q4/Full Year 2024 Results' press release, revenue for Stellest lenses increased by approximately 50% in China during the fourth quarter.

Advancements in Implantable Collamer Lens (ICL) technologies are simultaneously expanding surgical options for high myopia patients often unsuitable for corneal laser procedures. This reflects a technological pivot from subtractive techniques like LASIK to additive solutions that preserve corneal integrity. Manufacturers are enhancing these devices with wider refractive ranges, increasing surgeon confidence and patient acceptance. This segment is witnessing robust financial performance as procedure volumes rise. According to STAAR Surgical, October 2025, in the 'STAAR Surgical Announces Preliminary Net Sales Results for Third Quarter 2025' press release, the company reported preliminary net sales of $94.7 million, representing a 6.9% increase compared to the prior year period.

Segmental Insights

The Prescription segment denotes the fastest growing category within the Global Myopia and Presbyopia Treatment Market. This trend is primarily driven by the rising diagnosis of refractive errors necessitating precise optical or pharmaceutical correction. Furthermore, the authorization of new therapies by regulatory entities such as the US Food and Drug Administration has validated the efficacy of emerging prescription options. This regulatory support fosters greater reliance on clinically prescribed solutions for managing progressive myopia and age-related presbyopia. Consequently, the preference for verified prescription interventions is fueling substantial market expansion globally.

Regional Insights

North America maintains a dominant position in the global myopia and presbyopia treatment market, primarily due to its established healthcare infrastructure and the rising prevalence of vision disorders among the aging population. This leadership is supported by the proactive involvement of regulatory bodies like the U.S. Food and Drug Administration, which facilitates the approval and commercialization of new corrective technologies. Furthermore, the presence of major market players and widespread insurance coverage ensures high accessibility to treatments. Consequently, high healthcare expenditure and patient awareness continue to drive substantial market activity across the region.

Recent Developments

• In September 2025, LENZ Therapeutics announced the commercial availability of its new aceclidine-based ophthalmic solution in the United States, marking a significant development in the presbyopia treatment market. The company began distributing professional samples to eye care providers, with broader consumer access through retail pharmacies scheduled for the fourth quarter. This product, designed to improve near vision by creating a pinhole effect via pupil modulation, became the first pharmaceutical therapy of its class to enter the market. The organization highlighted that this launch represented a major milestone in addressing the needs of millions of adults affected by age-related near vision loss.
• In September 2025, EssilorLuxottica received authorization from the U.S. Food and Drug Administration for a novel spectacle lens intended to slow the progression of nearsightedness in children aged 6 to 12. Clinical trial data supporting the decision demonstrated that the lens reduced condition progression by 71% compared to standard lenses. This regulatory milestone marked the entry of the first spectacle-based intervention for this indication in the U.S. market, offering a non-invasive alternative to contact lenses. The company revealed plans to make the product available to eye care professionals across the country in the subsequent weeks.
• In December 2024, Tenpoint Therapeutics and Visus Therapeutics finalized a merger to combine their expertise in developing ophthalmic medicines for age-related eye conditions. The consolidated entity announced it would focus on advancing a late-stage, preservative-free eye drop designed to correct the loss of near vision associated with presbyopia. Alongside the merger, the organization secured crossover financing from a syndicate of institutional investors to fund the completion of ongoing clinical trials. The company stated that this strategic union aimed to accelerate the regulatory filing and potential commercial launch of their lead investigational therapeutic.
• In May 2024, Dopavision released topline results from its proof-of-concept clinical trial investigating a targeted photobiomodulation treatment for childhood myopia. The study assessed the safety and tolerability of a digital therapeutic that delivers light stimulation to the eye to regulate signaling pathways associated with eye growth. Findings indicated that the intervention was safe and well-tolerated over a six-month period, with preliminary data suggesting a clinical effect on the rate of condition progression. The Chief Executive Officer noted that these results supported further development of the non-invasive, digital alternative to traditional pharmacological and optical therapies.

Key Market Players

• Ziemer Ophthalmic Systems AG
• NIDEK CO., LTD.
• Johnson & Johnson Vision
• EssilorLuxottica.
• ZEISS Group
• Alcon Vision LLC
• Bausch + Lomb Corporation
• Haag-Streit UK
• Topcon Corporation

By Myopia Treatment Type	By Presbyopia Treatment Type	By Region
Corrective Surgical Drugs	Prescription Contact Lenses Intraocular Lenses Refractive Surgery	North America Europe Asia Pacific South America Middle East & Africa

Report Scope:

In this report, the Global Myopia And Presbyopia Treatment Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• Myopia And Presbyopia Treatment Market, By Myopia Treatment Type:

• Corrective
• Surgical
• Drugs

• Myopia And Presbyopia Treatment Market, By Presbyopia Treatment Type:

• Prescription
• Contact Lenses
• Intraocular Lenses
• Refractive Surgery

• Myopia And Presbyopia Treatment Market, By Region:

• North America
• United States
• Canada
• Mexico
• Europe
• France
• United Kingdom
• Italy
• Germany
• Spain
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• South America
• Brazil
• Argentina
• Colombia
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE